Abstract: The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD). and methods for the detection of CCR9, which make use of the binding molecules of the invention.

Abstract: The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.

Abstract: The disclosure provides compositions and methods that make use of a target protein that is capable of binding to a small molecule in order to form a complex, and a binding member that specifically binds to the complex, wherein the target protein is derived from a non-human protein and the small molecule is an inhibitor of the non-human protein. The non-human protein may be derived from a viral, bacterial, fungal or protozoal protein. These compositions and methods permit the controlled interaction of polypeptides that are individually fused to the target protein and binding member, respectively, and can be used to control the activity of dimerization-inducible proteins such as split transcription factors and split chimeric antigen receptors through the addition of the small molecule. The disclosure provides expression vectors, binding members, dimerization-inducible proteins, nucleic acids, cells, viral particles, kits, systems and methods that involve these components.

Abstract: The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.

Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PrPC. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.

Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PrPC. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.

Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PrPc. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.

Abstract: Novel anti-IL-13 antigen-binding proteins such as antibodies and antigen-binding fragments thereof are provided. Methods of using the proteins to reduce IL-13 activity and to treat IL-13-associated diseases and conditions are further provided.